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In human cancer cells, BAG3 protein is known to sustain cell survival. Here, for the first time, we demonstrate the
expression of BAG3 protein both in equine sarcoids in vivo and in EqS04b cells, a sarcoid-derived fully transformed
cell line harbouring bovine papilloma virus (BPV)-1 genome. Evidence of a possible involvement of BAG3 in equine
sarcoid carcinogenesis was obtained by immunohistochemistry analysis of tumour samples. We found that most
tumour samples stained positive for BAG3, even though to a different grade, while normal dermal fibroblasts from
healthy horses displayed very weak staining pattern for BAG3 expression. By siRNA technology, we demonstrate in
EqS04b the role of BAG3 in counteracting basal as well as chemical-triggered pro-death signals. BAG3 down-
modulation was indeed shown to promote cell death and cell cycle arrest in G0/G1. In addition, we found that
BAG3 silencing sensitized EqS04b cells to phenethylisothiocyanate (PEITC), a promising cancer chemopreventive/
chemotherapeutic agent present in edible cruciferous vegetables. Notably, such a pro-survival role of BAG3 was less
marked in E. Derm cells, an equine BPV-negative fibroblast cell line taken as a normal counterpart. Altogether our
findings might suggest a mutual cooperation between BAG3 and viral oncoproteins to sustain cell survival.Introduction
Sarcoids are the most common dermatological neo-
plasms affecting equids [1]. These neoplasms are benign
lesions of fibroblastic origin, that often occur at sites of
previous injury or scarring; they are locally aggressive
and invasive, but rarely metastasize [2]. Histologically,
the sarcoids are characterized by dermal proliferation of
fibroblasts, forming whorls and epidermal hyperplasia.
Although the pathology of this equine neoplasm is not
completely understood, bovine papillomavirus (BPV) is
considered to be the etiological agent. BPV type 1 and
type 2 (BPV-1/-2) are non-enveloped, double stranded,
DNA viruses, which commonly infect their natural host.
However, BPV-1, and less commonly BPV-2, have been
detected in sarcoids in different geographic areas of the
world [3]. The major transforming product of BPV is E5,
a very small membrane-associated protein with potent* Correspondence: mabelisa@unisa.it
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reproduction in any medium, provided the orbiological activities. It has been well recognized that E5
oncoprotein plays a key role during the development of
BPV-induced tumours [4]. E5 oncogene is transcription-
ally active and the protein is expressed in the neoplastic
fibroblasts and overlying hyperplastic epidermis of sar-
coids, where the BPV completes its life cycle producing
virion particles [5,6].
Apoptosis is a non-inflammatory death process acti-
vated by cells to escape from viral infections, since cell
death does not allow a complete viral replication cycle.
Therefore, virus, in turn, can activate signalling pathways
to prevent host cellular death [7]. The anti-apoptotic
cellular machinery includes several proteins, among
which the BAG family molecular chaperone regulator 3
(BAG3). BAG3, a member of a family of co-chaperones,
shares the conserved BAG domain by which it interacts
with heat shock proteins and other partners [8]. BAG3 is
overexpressed in several human tumours, where it sus-
tains cell survival through down-modulation of apop-
tosis [8,9]. bag3 gene expression may also be induced in
normal cells by several stressful agents [8,10,11] andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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plays an important role in the interaction of HIV-1 with
host cells, thus controlling virus infection [12,13]. In-
deed, in HIV-1 infected human microglia cells, BAG3
overexpression sustains cell survival by blocking
caspase-3 activation and interfering with Akt prote-
asome translocation. Moreover, it was shown that
BAG3 silencing inhibits Varicella Zoster Virus replica-
tion [14]. In Epstein Barr virus (EBV)-infected fibro-
blasts, apoptosis inhibition and a higher resistance to
cytotoxic drugs has been associated to positive modu-
lation of BAG3 and HSP70 expression by EBNA3A
oncoprotein, a member of EBV nuclear antigens [15].
In the present study we focused on a possible involve-
ment of BAG3 in equine sarcoid carcinogenesis. We
demonstrate that BAG3 is selectively expressed in sar-
coid tumour samples and highlight its pro-survival role




Fetal Bovine Serum (FBS) was from GIBCO (Life
Technologies, Grand Island, NY, USA). All the otherTable 1 Presence of BPV-1 and immunohistochemical express

















N2 Normal skin n
N3 Normal skin n
N4 Normal skin n
N5 Normal skin n
*T: tumour sample; N: normal skin sample.
**Immunoreactivity scoring was determined by two observers. The intensity of imm
very weak signal; +, weak signal; ++, moderate signal; +++, strong signal; n.a., not areagents were from Sigma-Aldrich (St. Louis, MO,
USA). Anti-BAG3 (TOS-2) and anti-BAG3 (AC-1 clone)
(BIOUNIVERSA, Fisciano, SA, Italy), anti-GAPDH (mou
se monoclonal, sc-32233), anti-α tubulin (mouse mono-
clonal, sc-32293), anti-β actin (mouse monoclonal, sc-
47778) from Santa Cruz Biotechnology (Santa Cruz, CA,
USA); appropriate peroxidase-conjugated secondary anti-
bodies were from Jackson ImmunoResearch (Baltimore,
PA, USA).
Tumour samples
A total of 15 equine sarcoids of different clinical types
(Table 1) were evaluated. Normal skin samples from
five healthy horses were also examined. Sections taken
from paraffin blocks were stained by haematoxylin and
eosin and re-evaluated to confirm the diagnosis.
Histologically, the samples were characterised by epi-
dermal hyperplasia with rete peg invading the dermal
tissue beneath. A diffuse proliferation of dermal fibroblasts
arranged in whorls and/or bundles was seen. All the
tumour samples were diagnosed as equine sarcoids.
All tumours were known to harbour BPV DNA [5].
Six out of 15 sarcoids and one normal skin sample were
immediately frozen at −80°C until biochemical analysis.ion of BAG3 in equine sarcoids





















une labelling for each specimen was scored on a four-tiered scale: +/−,
ssessable.
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Fifteen sarcoid samples (T1-T15) and 5 normal skin
samples (N1-N5) were stained. Briefly, paraffin sections
were deparaffinised and blocked for endogenous perox-
idase in 0.3% H2O2 in methanol for 20 min. Antigen
enhancement was performed by pretreating with micro-
wave heating (twice for 5 min each at 525 W). The anti-
BAG3 antibody (AC-1 clone) was applied at 1:600
dilutions in phosphate-buffered saline (PBS) overnight
at room temperature in a humidified chamber. The
slides were washed three times with PBS and then in-
cubated for 30 min with the appropriate biotinylated
secondary antibody (labelled streptavidin–biotin (LSAB)
Kit; DakoCytomation, Denmark) as previously reported
[16]. Sections were washed three times with PBS
and then incubated with streptavidin-conjugated to
horseradish peroxidase (LSAB Kit; DakoCytomation,
Denmark). Colour development was obtained by
treatment with diaminobenzidine (DakoCytomation,
Denmark) for 5 min. Sections were counterstained with
Mayer’s haematoxylin. In the corresponding negative
control section, the primary antibody was either omitted
or replaced with appropriate normal serum. Due to
technical issues associated with tissue loss during anti-
gen retrieval, it was not possible to perform staining for
BAG3 in 2 tumour samples (T9 and T13). The scoring
of the immunoreactivity was determined in a “blind”
study by two observers (GB and AC). The intensity of




EqS04b cell line is a fully transformed sarcoid fibroblast
line harbouring episomal BPV-1 genome. This line was a
kind gift of Prof. L. Nasir (University of Glasgow,
Scotland), who previously characterised and described it
[17]. E. Derm fibroblast cell line, derived from horse
dermis, and HeLa cells, human epithelioid cervix carci-
noma cells expressing HPV-18 genome, were obtained from
American Type Culture Collection (ATCC) (Manassas, VA,
USA). All cells were maintained in DMEM
(Biowhitaker, Lonza, NJ, USA) medium, supplemented
with 10% (v/v) FBS, 2 mM L-glutamine and antibiotics,
at 37°C in humidified 5% CO2 atmosphere. To ensure
logarithmic growth, the cells were sub-cultured every
three days.
Transfection
A specific small interfering RNA (siRNA) (5’-AA
GGUUCAGACCAUCUUGGAA-3’) targeting bag3 mRNA
and a control, non-targeted (scr) RNA (5’-CAG
UCGCGUUUGCGACUGG-3’) were obtained from
Dharmacon (Thermo Fisher Scientific, Lafayette, CO,USA). EqS04b and E. Derm cells, at a density of 1 ×
105/mL, were transfected with siRNA and scrRNA at
final concentration of 500 nM using lipofectamine™
RNAiMAX reagent (Invitrogen, Life Technologies, Grand
Island, NY, USA). The cells were harvested at the time
points indicated and BAG3 silencing was monitored in all
the experiments by Western blotting. Human and equine
siRNA targeting regions were compared (see Additional
file 1) using Vista Browser 2.0 [18].Protein extraction and SDS PAGE/Western blotting
Six sarcoids (T1; T2; T3; T4; T5; T6) and one sample of
normal skin (N1) were available for molecular analysis.
These were snap frozen in liquid nitrogen and
homogenised in ice-cold lysis buffer (50 mM Tris pH
7.5; 150 mM NaCl; 1 mM EDTA; 0.25% deoxycholic
acid, 1% Triton X-100) added with 20 mM sodium
pyrophosphate, 0.1 mg/mL aprotinin, 2 mM phenylmethy
lsulfonyl fluoride (PMSF), 10 mM sodium orthovanadate
(Na2VO3), and 50 mM NaF. EqS04b, E. Derm and HeLa
whole lysates for immunoblot analysis were prepared
according to the standard protocol.
Tissue homogenates and cell lysates were clarified by
centrifugation and protein concentration was deter-
mined by DC Protein Assay (Bio-Rad, Berkeley, CA,
USA), using bovine serum albumin (BSA) as a standard.
Proteins were fractionated on SDS-PAGE, transferred
into nitrocellulose membranes, and immunoblotted with
appropriate primary antibodies. Signals were visualised
with appropriate horseradish peroxidase-conjugated
secondary antibodies and enhanced chemiluminescence
(Amersham Biosciences-GE Healthcare, NY, USA). Densi-
tometry of bands was performed with ImageJ software
(NHI, USA). The area under the curves, each relative to a
band, was determined and the background was subtracted
from the calculated values.Cell viability and drug treatment
Control and transfected cells, at a density of 1.2 × 105/
mL, were plated in 96 well-plates one day before the be-
ginning of treatment with chemotherapeutics to allow cells
to firmly adhere. Increasing doses of etoposide, tumour ne-
crosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL), and phenethylisothiocyanate (PEITC) were added
and plates were incubated for a further 24 h. At the end of
incubation time, the number of viable cells was quantified
by MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide]) assay. Absorption at 550 nm was assessed
using a microplate reader (LabSystems, Vienna, VA, USA).
MTT assay was also adopted to evaluate the effect of
scrRNA and siRNA transfection on cell viability. In some
experiments cell viability was also measured by Trypan
Blue exclusion assay using a Bürker counting chamber.
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flow cytometry
Cellular DNA content was evaluated by propidium iod-
ide (PI) staining of permeabilised cells according to the
protocol available [19]. Data from 5000 events per sam-
ple were collected. The percentages of the elements in
the hypodiploid region and in G0/G1, S, G2/M phases of
the cell cycle were calculated using the CellQuest or
MODFIT software, respectively (Becton Dickinson, San
Jose, CA, USA).
Apoptosis was determined by Human Annexin V/FITC
kit (Bender MedSystem, Vienna, Austria) according to the
manufacturer’s instructions. Green (Annexin V-FITC) and
red (PI) fluorescence of individual cells were measured by
flow cytometry. Electronic compensation was required to
exclude overlapping of the two emission spectra.
Analysis of PEITC-induced detachment
Culture media of scrRNA- and BAG3siRNA-transfected
cells were changed 42 h following transfection to remove
detached or died cells. PEITC or vehicle only were then
added and cells were incubated for the times indicated.
Non-transfected cells were included as an internal con-
trol. Phase contrast microscopy images were acquired
after 6 h incubation. A parallel set of plates was incu-
bated for a further two hours and used, after carefully
removing media, to measure the number of still attached
cells by MTT assay.
Microscopy analysis
Phase contrast microscopy analysis was performed using
a Leica DM IL LED microscope (Leica Microsystems,
Wetzlar, Germany) equipped with a 40 × objective and
images were acquired from randomly selected fields.
Statistical analysis
Unless otherwise specified, data reported in each figure
are the mean value ± S.E.M. of at least three experi-
ments performed in duplicate. Differences between
treatment groups were analysed by the student t test.
Differences were considered significant when p < 0.05.
Results
BAG3 expression in equine sarcoids
We analysed immunohistochemically 15 tumour sam-
ples and 5 normal skin samples for BAG3 expression
(Table 1). Thirteen out of 15 tumour samples stained
positive for BAG3 (85%). Four out of 13 samples (30%)
showed strong immunoreactivity; 5 out of 13 (40%)
displayed a moderate immunostaining signal; the
remaining sarcoid samples, showed a weak (15%) and a
very weak (15%) immunostaining signal for BAG3
throughout the lesions. In the positive samples the im-
munoreactivity was observed in almost all neoplasticfibroblasts (Figure 1a). Normal dermal fibroblasts de-
rived from healthy horses displayed very weak staining
patterns for BAG3 expression (Figure 1b). Samples (T1-
T6 and N1) were analysed biochemically and the
anti-BAG3 antibody recognised a band of the expected
molecular weight in all samples examined (data not
shown).
BAG3 down-modulation in equine cell lines
BAG3 expression was also monitored in whole lysates of
EqS04b and E. Derm cells by Western blotting. Human
HeLa cells were included as a control [20]. As shown in
Figure 2a, BAG3 protein signal was successfully detected
in both equine cell lines. Notably, the levels of BAG3
were higher in a sarcoid-derived EqS04b cell line than in
E. Derm cells, taken as the normal counterpart.
Since BAG3 anti-apoptotic effect in human tumour
cell lines has been well established [8,9], we aimed at
evaluating whether BAG3 might have a pro-survival role
also in EqS04b and E. Derm cells. To this end, BAG3
protein expression was down-modulated by using a
BAG3-specific siRNA (BAG3siRNA) and cell viability
was monitored. Cells transfected with scrambled RNA
(scrRNA) and non-transfected cells were included as
controls. Figure 2b shows that reduction of BAG3 levels
in siRNA-transfected cells was already detectable at 48
h, becoming more evident at 72 h. However, complete
BAG3 knock-down failed, even using a BAG3siRNA
concentration two fold higher than that used for BAG3
full silencing in human cells [9].
Then, we evaluated the effect of BAG3 silencing on
cell number (Figure 3a). The number of EqS04b viable
cells, at 48 h and 72 h following BAG3siRNA transfec-
tion, was about 72% and 51%, respectively, of that in
scrRNA-transfected cells. A time-dependent decrease of
cell number, even though less marked, was also observed
in the E. Derm cell line. It should be underlined that
transfection procedure caused per se a slight reduction
of cell number in both cell lines probably due to a loss
of attachment efficiency. In particular, the number of
scrRNA-treated EqSO4b and E. Derm cells was, irre-
spective of the times following transfection, about 11% ±
1.3 and 13% ± 1.6, respectively, lower than in their rela-
tive non-transfected controls.
Light microscopy images in Figure 3b revealed that
BAG3siRNA transfection caused most of the EqS04b
cells to acquire a round shaped morphology, ultimately
resulting in cell detachment and death. Similar results
were also obtained, even though less marked, in
BAG3siRNA-transfected E. Derm cells (data not shown).
BAG3 silencing induces apoptosis and cell cycle arrest
Since in preliminary experiments we found that BAG3
silencing elicited qualitatively, but not quantitatively,
Figure 1 BAG3 expression in equine sarcoid and normal fibroblasts. (a) Neoplastic fibroblasts from equine sarcoid show strong
immunoreactivity for BAG3. Streptavidin-biotin peroxidase method. Mayer’s haematoxylin nuclear counterstain ×240. (b) Dermal fibroblasts from
normal equine skin are weakly immunostained for BAG3. Streptavidin-biotin peroxidase method. Mayer’s haematoxylin nuclear counterstain ×120.
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results obtained with EqS04b cells.
EqS04b transfected with BAG3siRNA were collected
at 36 h and 56 h following transfection and were stained
under permeabilising conditions with propidium iodide
(PI), a DNA intercalating agent. They were then ana-
lyzed by flow cytometry to discriminate cell populations
on the basis of their DNA content. ScrRNA-transfected
cells were included as controls. Data summarised inFigure 2 BAG3 expression and down-modulation in equine and huma
and human HeLa cell total extracts were analysed by Western blotting for
control. Blot is from one experiment representative of at least two with sim
down-modulation in EqS04b and E. Derm cells. EqS04b and E. Derm cells w
(scrRNA). Non-transfected cells were included as controls (Ctrl). At the time
blotting for BAG3 levels. The blots were also probed for tubulin as the load
two with similar results.Figure 4a show that BAG3 down-modulation caused a
time-dependent increase of cells with a subG0/G1 DNA
content (< n, hypodiploid cells), indicative of the apop-
totic mode of cell death. In addition, the percentages of
BAG3-silenced cells in G0/G1 (DNA content = n) were
significantly higher, especially at 36 h, than in scrRNA-
transfected cells. Because of the high percentage of
subG0/G1 cells at 56 h, we could argue that the less
marked cell cycle impairment observed at that timen cell lines. (a) BAG3 expression in equine cell lines. EqS04b, E. Derm
BAG3 levels. The blots were also probed for tubulin as the loading
ilar results. On the right: densitometry analysis of bands. (b) BAG3
ere transfected with BAG3siRNA (siRNA) or a non-targeting siRNA
s indicated, total cell extracts were prepared and analysed by Western
ing control. Blots are from one experiment representative of at least
Figure 3 Effect of BAG3 down-regulation on cell viability and morphology. (a) Number of viable cells in BAG3-silenced EqS04b and E. Derm
cells at 48 h and 72 h following transfection. Data, expressed as a percentage of the number of scrRNA-transfected viable cells measured at the
same times, are the mean values ± S.E.M. from at least three experiments (*p < 0.05, **p < 0.001 versus scrRNA-treated cells); (b) Phase contrast
microscopy images of non-transfected (Ctrl), scrRNA- and BAG3siRNA (siRNA)-transfected EqS04b samples at 56 h after transfection. Images are
from one analysis representative of at least three experiments with similar results.
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in cells previously accumulated in G0/G1, rather than to
a recovery of normal cell cycle progression.
Next, because cells integrated as subG0/G1 may
include not only frankly apoptotic cells, but also necrotic
fragments, we took advantage of Annexin V/PI assay to
discriminate between the two different modes of cell
death. BAG3siRNA- and scrRNA-treated EqS04b cells
were double stained, under non-permealizing conditions,
with Annexin V, which binds phosphatidyl serine (PS)
residues exposed on membranes of apoptotic cells, and
PI, which can penetrate only in cells with compromised
plasma membrane, such as late apoptotic and necrotic cells.
Data summarised in Figure 4b show a time-dependent
increase of PS positive cells (Annexin V+/PI-, early apop-
tosis and Annexin V+/PI+, late apoptosis) in BAG3siRNA-
respect to scrRNA-transfected EqS04b cells. A switch
from an apoptotic to a necrotic mode of cell death was ob-
served only at 56 h following BAG3siRNA transfection.
These findings indicate that BAG3 down-regulation pro-
moted equine cell death primarily by apoptosis.
BAG3 down-modulation sensitizes equine cell lines to
chemical-induced toxicity
Next we aimed at verifying whether BAG3 down-
regulation, in addition to sensitising cells to basal apop-
totic signals, might also increase EqS04b and E. Derm
response to drugs, known to promote apoptosis in
human tumour-derived cell lines. First of all, we
characterised EqS04b and E. Derm cells for theirresponse to three pro-apoptotic chemicals, each acting
by a different main mechanism. In particular, we tested
etoposide, an inhibitor of topoisomerase II [21], TRAIL,
which activates extrinsic pathway of apoptosis [22], and
PEITC, which promotes a mitochondrial-mediated in-
trinsic pathway of apoptosis [23]. Human HeLa cells
were included in the experiments. Cells were exposed to
increasing doses of each chemical and, after 24 h incuba-
tion, the number of cells was measured by MTT assay.
The Ic50 values (the amount of drug required to inhibit
cell growth by 50%) in the three cell lines were calcu-
lated from the respective dose–response curves (Table 2).
EqS04b and, to a lower extent, E. Derm cells were mark-
edly more resistant to etoposide and TRAIL than human
HeLa cells. Conversely, both equine cell lines were
highly susceptible, with E. Derm displaying the highest
susceptibility, to PEITC.
To assess whether BAG3 might play some roles in
equine cell response to PEITC, we monitored the effect
of increasing PEITC doses on BAG3 protein levels. Blots
reported in Figure 5 show that EqS04b exposure for 12
h to PEITC doses lower than the Ic50 value led to in-
creased BAG3 protein expression. Conversely, BAG3
levels were dramatically reduced at 30 μM PEITC, a
dose at which cells were already committed towards an
irreversible death fate. Modulation of BAG3 expression
by PEITC was also observed in the E. Derm cell line
(data not shown). The blot in Figure 5 was re-probed for
tubulin, taken as a marker of PEITC effectiveness. In
preliminary experiments, we, indeed, confirmed that
Figure 4 BAG3 down-regulation induces apoptosis and affects cell cycle progression in EqS04b cells. (a) On the Y axis, the percentages
of hypodiploid cells (subG0/G1) and of cells in each cell cycle phase of BAG3siRNA-transfected EqS04b cells subtracted for the corresponding
percentages in scrRNA-transfected cells. Data presented are the mean values ± S.E.M. from at least three experiments (*p < 0.05, **p < 0.001
calculated on raw data of BAG3siRNA-silenced versus scrRNA-treated cells). Mean values (%) ± S.E.M. in scrRNA-transfected cells: i) at 36 h, subG0/
G1 4.9 ± 1.2; G0/G1 68.59 ± 3.7; S 21.08 ± 1.8; G2/M 9.03 ± 1.0; ii) at 56 h, subG0/G1 3.5 ± 1; G0/G1 66.8 ± 2.3; S 22.4 ± 2.1; G2/M 10.6 ± 1.1.
Representative histograms of cell cycle profiles of scrRNA- and BAG3siRNA-transfected cells at 36 h are on the left. (b) On the Y axis, the
percentages of Annexin V positive (A+/PI-, early apoptotic cells; A+/PI+, late apoptotic cells) and necrotic cells (A-/PI+) in BAG3siRNA-silenced
EqS04b cells subtracted for the corresponding percentages in scrRNA-transfected cells. Data presented are the mean values ± S.E.M. from at least
three experiments (*p < 0.05, **p < 0.001 calculated on raw data of BAG3siRNA-silenced versus scrRNA-treated cells). Mean values (%) ± S.E.M. in
scrRNA-transfected cells: i) at 36 h, A+/PI-, 4.2 ± 1.1; A+/PI+, 2.3 ± 0.96; A-/PI+, 3.1 ± 1; ii) at 56 h the values became comparable to those of
non-transfected control cells (≤ 2% in A+/PI-, A+/PI+, A-/PI+ gated quadrants).
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as previously demonstrated in human cell lines [24,25].
The observed BAG3 modulation by PEITC prompted
us to investigate whether BAG3 down-regulation could
actually lead to an increase of EqS04b and E. Derm sus-
ceptibility to the chemical. We carefully designed anTable 2 Cell growth inhibition potency (Ic5024 h) of





EqS04b 150 ±12* >1500 ng/mL 25 ± 1.9
E. Derm 80 ± 10 >1000 ng/mL 19 ± 1.5
HeLa 30 ± 2.2 30 ng/mL 12.5 ± 0.9
* Mean values ± S.E.M.
Figure 5 PEITC modulates BAG3 protein levels. Cell extracts
from EqS04b cells exposed to the indicated doses of PEITC for 12 h
were monitored for BAG3 levels. Actin levels were checked as the
loading control. Filters were also probed for PEITC-induced tubulin
degradation. Blot is from one experiment representative of at least
two with similar results.
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results. In particular, we adopted the following experi-
mental conditions: i) PEITC was added at 42 h following
transfection, a time at which the number of BAG3-
silenced viable EqS04b and E. Derm cells was reduced
by only 25% and 20%, respectively, compared to the cor-
responding scrRNA-transfected cells; ii) to take into ac-
count such a reduction, the doses of PEITC added to
BAG3-silenced EqS04b and E. Derm cells were 25% and
20%, respectively lower than those used for the corre-
sponding non-transfected and scrRNA-transfected con-
trols. Moreover, to completely avoid overlap between
PEITC-induced toxicity and BAG3 silencing–induced
cell death, we took advantage of PEITC short-term
treatment-induced cellular morphological changes. In
particular, treatments of non-transfected EqS04b and E.
Derm cells with PEITC doses lower than the respective
Ic50 values for 1 h caused cells to acquire a round
shaped morphology, but already after 6 h of incubation,
the cells were able to restore multiple contacts with the
extracellular matrix and spread (Figure 6a, left panels).
Quite similar results were obtained when we monitored
the effect of PEITC short-term treatment on scrRNA-
transfected cells. Cells were still able to recover an elon-
gated fibroblastoid shape, but less efficiently than controlFigure 6 BAG3 down-modulation sensitizes equine cell lines to PEITC
were exposed to PEITC 42 h after transfection. Control and scrRNA-treated
PEITC, respectively, while EqSO4b and E. Derm BAG3 silenced cells (siRNA)
lower number of cells (about 70-80% of control and scrRNA cells). (a) Phas
panels), and BAG3siRNA (siRNA)-transfected (right panels) cells were acquir
of three with similar results). (b) Percentages of adherent cells at 8 h follow
BAG3siRNA (siRNA)-transfected cells respect to their corresponding control
from at least three experiments (*p < 0.05, **p < 0.001; scrRNA-transfectedcells, possibly because the transfection procedure may
per se affect membrane structure/permeability to PEITC
(Figure 6a, middle panels). Conversely, microscopy ana-
lysis of BAG3-silenced cells clearly showed that most of
the PEITC-treated cells remained round shaped, aggre-
gated and detached (Figure 6a, right panels). Remark-
ably, PEITC-induced detachment seemed less marked in
BAG3-silenced E. Derm cells than in EqS04b. These re-
sults were taken as evidence, even if only qualitative,
of an increased susceptibility of EqS04b and, less
markedly, of E. Derm cells to PEITC upon BAG3
down-modulation.
To confirm and quantify the results obtained by phase
microscopy analysis, we performed an ad hoc experi-
ment. At 42 h following transfection, scrRNA- and
BAG3siRNA-transfected cells were treated according to
the above procedure with PEITC or vehicle only. After 8
h incubation, media, containing floating cells, were care-
fully removed to measure still adherent cells by MTT
assay. The number of cells in PEITC-treated samples is
expressed as the percentage of that in vehicle–treated
respective controls. Data summarized in Figure 6b con-
firmed microscopy results. In fact, scrRNA-transfected
EqS04b and E. Derm resulted more susceptible, even
slightly, to PEITC than non-transfected cells. A largely-induced detachment. Control, scrRNA- and BAG3siRNA-treated cells
(scrRNA) EqS04b and E. Derm cells were exposed to 20 μM and 15 μM
were exposed to 15 μM and 12 μM PEITC, respectively, in view of the
e contrast images of control (left panels), scrRNA-transfected (middle
ed at the times indicated (images from one experiment representative
ing PEITC treatment in non-transfected (ctrl), scrRNA-transfected, and
s exposed to vehicle only. Data presented are the mean values ± S.E.M.
versus non-transfected or siRNA versus scrRNA).
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BAG3-silenced cells exposed to PEITC. Notably, while
in E. Derm the percentage of attached cells was about
50% of the corresponding vehicle-treated control, in
EqS04b the value dropped to about 25%, thus unequivo-
cally demonstrating that BAG3 efficiently counteracts,
especially in BPV-1 positive cell death signals triggered
by PEITC. These results were qualitatively confirmed by
microscopic counting, upon concentration by centrifuga-
tion, of floating cells in collected media (data not shown).Discussion
In human cancer cells, BAG3 protein is known to sus-
tain cell survival [8,26]. Overexpression of bag3 pro-
motes, indeed, survival whereas its down-regulation
sensitizes cells to apoptosis, both in vitro and in vivo
[8,9,26]. In the present study, for the first time, we dem-
onstrate that BAG3 protein is expressed in a subset of
naturally occurring equine sarcoids, expressing BPV-1
genome, and that it sensitizes equine sarcoid-derived
cells to PEITC, a promising cancer chemopreventive/
chemotherapeutic agent present in edible cruciferous
vegetables [27].
The first evidence of a possible involvement of BAG3
in equine sarcoid carcinogenesis was obtained by immu-
nohistochemistry analysis of tumour samples. We found
that 13 out of 15 tumour samples stained, even though
to a different grade, positive for BAG3. Notably, normal
dermal fibroblasts derived from healthy horses displayed
a very weak staining pattern for BAG3 expression. Sar-
coids may exist as six different clinical types. We did not
find any correlation between overexpression of BAG3
and clinical appearance, suggesting the existence of a
common mechanism underlying the up-regulation of
protein expression, that acts early during the develop-
ment of equine sarcoids.
To get more insight into a possible pro-survival role of
BAG3 in sarcoids, biochemical studies were conducted
on EqS04b cells, an equine sarcoid-derived BPV-1 posi-
tive cell line [17], as an in vitro model. We found that
EqS04b cells express higher levels of BAG3 than E.
Derm cells, taken as the normal counterpart. Moreover,
by means of siRNA technology, we demonstrated that
BAG3 down-regulation induced, more markedly in
EqS04b than in E. Derm cells, apoptotic death and cell
cycle arrest in G0/G1. These findings support the idea of
some cooperation between BAG3 and viral oncoproteins
in sustaining cell survival and proliferation.
Because BAG3 has been shown to underlie resistance
to chemotherapy [28], and considering that, currently,
there is no 100% effective therapy for the treatment of
equine sarcoids [3], we would investigate whether the
lack of BAG3 function might specifically sensitize BPV-1positive EqS04b cells to potentially chemotherapeutic
agents.
The analysis of the basal response to etoposide and
TRAIL, two well known anti-tumour chemicals in
humans [29], showed that both equine cell lines were
very low, if not, susceptible to these cell-killing agents.
In particular the lack of any significant response to
TRAIL could be explained on the basis of dissimilarity
between equine and human death receptors, DR4
(TRAIL-RI) and DR5 (TRAIL-RII). In fact, comparison
between human and equine receptor sequence by com-
positional matrix adjust method showed identities =
43%, positives = 54%, gaps = 17% [18]. Conversely, we
found that both equine cell lines were highly susceptible
to PEITC. Interestingly, EqS04b displayed lower suscep-
tibility to PEITC, as well as to etoposide, than E. Derm
cells thus supporting the hypothesis that the BPV
genome present in EqS04b provides some protection
against exogenous death stimuli. This hypothesis was
also supported by other studies on BPV-induced bovine
urinary bladder tumours in which high levels of E5 were
found to correlate with BAG3 overexpression (F. Roperto,
personal communication). However, our data seem to be
in contrast with those reported in the study of Finlay et al.
[30], who provided evidence that the presence of the BPV-
1 genome is, rather, associated to increased sensitivity of
equine sarcoid-derived cells to UVB- and cisplatin-
induced apoptosis. Such a discrepancy between their and
our findings might possibly be due to the use of different
cell-killing agents, which, acting by different mechanisms,
may interfere with specific cell death/survival signalling
pathways.
Subsequent experiments demonstrated that BAG3 is a
key component of the multifaceted pro-survival machin-
ery activated by equine cells as a primary response to
PEITC pro-death signals. In fact, exposure of cells to
low PEITC doses (lower than Ic50) caused an increase of
BAG3 levels. On the contrary, at highly cytotoxic PEITC
doses (higher than the Ic50 value) BAG3 levels were re-
duced thus suggesting that down-regulation of BAG3
was a prerequisite for commitment of cells towards an
irreversible death fate. Targeting BAG3, which is known
to prevent mitochondrial cytochrome c release [31] and
apoptosome assembly [8], allowed PEITC to activate
mitochondrial-mediated apoptosis.
At least, by siRNA technology we unequivocally dem-
onstrated the role of BAG3 in counteracting PEITC-
triggered pro-apoptotic signals. In fact, BAG3 down-
modulation sensitised equine cells to PEITC-induced cell
detachment and subsequent cell death. The central role
of BAG3 in cell adhesion pathways and, consequently, in
tumour invasion and metastasis, has been previously
demonstrated in human epithelial cancer cells [32,33].
Remarkably, the observed protective role of BAG3
Cotugno et al. Veterinary Research 2013, 44:61 Page 10 of 11
http://www.veterinaryresearch.org/content/44/1/61against PEITC-promoted cell detachment and death
resulted largely more relevant in BPV-1 infected cells. In
fact, the increased susceptibility to PEITC upon BAG3
silencing was in EqS04b cells about two fold higher than
in E. Derm cells. This result could be taken as a further
support of the presence of some positive cooperation be-
tween BAG3 and BPV-1 oncoproteins.
It could be hypothesised that BAG3 is effective in
preventing HSP70-mediated delivery to proteasome [34]
of BPV-1 oncoproteins. Indeed, BAG3-HSP70 interaction
in virus-infected human cells has been documented [14,15].
It has been shown that BAG3 co-localizes in the nucleus of
melanoma cells with HSC70/HSP70, HSP90 and ORF29p,
a LAP (latency associated protein) produced by Varicella
Zoster Virus [14]. Moreover, it is worthwhile noting that
HSP70 was found as a molecular partner of BPV E7
oncoprotein in sarcoid biopsies (manuscript in prepar-
ation). These examples of interaction with viral proteins
and/or involvement of BAG3 in viral replication pathways
suggest that also in our system BAG3 could someway inter-
act with BPV-1 oncoproteins, thus sustaining EqSO4b
BPV-1 positive cell survival.
We cannot exclude, however, that BPV-1 oncoproteins
are, rather, responsible for overexpression of anti-
apoptotic proteins, such as BAG3, in sarcoids. It is anec-
dotically reported that sarcoids arise in body areas where
irritation/inflammation occurs. Since BAG3 gene expres-
sion is induced by stressful agents, through the activa-
tion of heat shock factor (HSF-1) [9], we could also
speculate that a BAG3 increase is likely part of cell re-
sponse to injury, which, in turn, triggers/sustains BPV
viral oncoprotein expression.
In conclusion, this study reveals, for the first time,
the high susceptibility of sarcoid-derived BPV-1 posi-
tive EqS04b cell line to the natural compound PEITC,
and highlights the role of BAG3 protein to protect
these cells against PEITC-triggered pro-death signals.
Thus our findings, indicating BAG3 as a potential
therapeutic target, may provide useful information to
identify appropriate and efficient therapeutic strategy
for bovine papillomavirus infections.Additional file
Additional file 1: Comparison of human and equine siRNA
targeting regions. Comparative sequence analysis of human and horse
bag3 mRNA sequence (NM_004281.3 GI:62530382 and XM_001496279.3
GI:338716418) was performed by using VISTA Browser tool [18]. Homo
sapiens sequence was selected as the reference so the level of
conservation between this reference and horse (equus caballus) bag3
mRNA sequence was displayed. Conserved regions are highlighted under
the curve, with different colors used for coding (purple) and noncoding
sequences (grey), default values for conservation cutoff (X% over Y bp)
were used. A zoom of the siRNA targeting region is displayed (in the red
circle) and the arrow shows the one base mismatch between the human
sequence (siRNA target sequence) and the horse sequence.Abbreviations
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